Surveillance of Pancreatic Health After Diabetes Diagnosis

Prior treatment

• Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
• Solid organ transplant recipient

Other illness

• A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
• Under investigation for or confirmed pancreatic cancer
• Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years

Lab values

• Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.

Other

• Under investigation/surveillance for pancreatic cyst
• BMI \> 40 at the time of consent
• Blood transfusion within 1 month
• Currently pregnant
• Needing dialysis

• 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
• Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
• Willing to provide up to 30 mL of blood for each study visit
• Willing and eligible to undergo MRI or CT scan
• Understands the study process and is willing to take part in the study and sign the informed consent form